Los Angeles – September 17, 2026 -- The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Armata Pharmaceuticals' AP-SA02, an intravenous multi-phage candidate for complicated Staphylococcus aureus bacteremia, stacking the designation atop existing Fast Track and Qualified Infectious Disease Product status.
Phase 2 data show 100% relapse-free response versus 75% for placebo
The designation rests on results from the Phase 1b/2a diSArm study, in which AP-SA02 added to best available antibiotic therapy produced higher and earlier clinical cure rates than antibiotics alone. At the 28-day post-treatment assessment, 100% of AP-SA02 patients maintained clinical response without relapse, compared with 75% of patients on placebo plus antibiotics. The repeat-dosing regimen, administered intravenously every six hours for five days, showed no serious adverse events attributed to the drug and produced faster normalization of C-reactive protein and Interleukin-10, biomarkers linked to mortality risk in bloodstream infections.
Armata targets first antibacterial approval based on superiority over standard of care
Dr. Deborah Birx, Chief Executive Officer of Armata, said the FDA's action reflects the unmet need in complicated S. aureus bacteremia, including methicillin-resistant strains, where outcomes remain poor under current treatment. She said the company believes AP-SA02, if confirmed in Phase 3 and approved, could become the first antibacterial therapy cleared on superiority grounds over existing standard-of-care regimens.
Defense funding backs $28.7 million toward Phase 3 preparation
Clinical development of AP-SA02, including End-of-Phase 2 activities and Phase 3 readiness, is partially funded by a $28.7 million Department of War award administered through the Medical Technology Enterprise Consortium and the Naval Medical Research Command's Naval Advanced Medical Development division, with support from the Defense Health Agency and Joint Warfighter Medical Research Program. Armata plans to initiate a Phase 3 superiority study in complicated S. aureus bacteremia in the second half of 2026. Positive Phase 2a diSArm data were presented in a late-breaking oral session at IDWeek 2025 in October 2025.